ALKS as reported
Alkermes plc reported $1.56B of revenue over the trailing twelve months, +3.2% on the year before. 11 reported series are charted on this page, each one as filed.
$1.56B
Revenue, trailing twelve months · to Q1 2026 · +3.2% against the twelve months before
- Net Income
- $153M
Net Income · −57% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $222M
Free Cash Flow · −54% year on year · trailing twelve months to Q1 2026
- Op Margin
- 12%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $1.56B | +3.2% | Q1 2026 |
| Net Income | $153M | −57% | Q1 2026 |
| EPS | $0.90 | −57% | Q1 2026 |
| Gross Margin | 87% | n/a | Q1 2026 |
| Op Margin | 12% | n/a | Q1 2026 |
| Net Margin | 9.8% | n/a | Q1 2026 |
| ROE | 16% | n/a | Q1 2026 |
| ROA | 11% | n/a | Q1 2026 |
| ROIC | 41% | n/a | Q3 2024 · 6 quarters behind |
| Free Cash Flow | $222M | −54% | Q1 2026 |
| P/E | 54.6 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Alkermes plc (ALKS) - Revenue & ProfitRevenue & ProfitAlkermes plc (ALKS)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #21 of 28 by Smart Score